scispace - formally typeset
Journal ArticleDOI

Gut microbiota and microbiome in schizophrenia.

Reads0
Chats0
TLDR
In this article, the authors performed a narrative review of studies addressing gut microbiota alterations in patients with schizophrenia that were published in the years 2019-2020 and concluded that findings from clinical trials do not support the use of probiotics as add-on treatments in schizophrenia.
Abstract
Purpose of review Accumulating evidence indicates that there are bidirectional interactions between the gut microbiota and functioning of the central nervous system. Consequently, it has been proposed that gut microbiota alterations might play an important role in the pathophysiology of schizophrenia. Therefore, in this article, we aimed to perform a narrative review of studies addressing gut microbiota alterations in patients with schizophrenia that were published in the years 2019-2020. Recent findings Several studies have shown a number of gut microbiota alterations at various stages of schizophrenia. Some of them can be associated with neurostructural abnormalities, psychopathological symptoms, subclinical inflammation and cardiovascular risk. Experimental studies clearly show that transplantation of gut microbiota from unmedicated patients with schizophrenia to germ-free mice results in a number of behavioural impairments accompanied by altered neurotransmission. However, findings from clinical trials do not support the use of probiotics as add-on treatments in schizophrenia. Summary Gut microbiota alterations are widely observed in patients with schizophrenia and might account for various biological alterations involved in the cause of psychosis. However, longitudinal studies are still needed to conclude regarding causal associations. Well designed clinical trials are needed to investigate safety and efficacy of probiotics and prebiotics in schizophrenia.

read more

Citations
More filters
Journal ArticleDOI

Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction

TL;DR: Although the pathophysiology and mechanisms of oxytocinergic dysfunction in metabolic syndrome and schizophrenia are both complex and it is still too early to draw a conclusion upon, oxytoc inergic dysfunction may yield a new mechanistic insight into schizophrenia pathogenesis and treatment.
Journal ArticleDOI

Altered gut microbiota and its metabolites correlate with plasma cytokines in schizophrenia inpatients with aggression

TL;DR: In this article , the authors determined the gut microbiota and its metabolites, and clarified their correlations with inflammation, oxidation, leaky gut and clinical profiles underlying aggression in schizophrenia (ScZ).
Journal ArticleDOI

The current state of research for psychobiotics use in the management of psychiatric disorders–A systematic literature review

O. Vasiliu
TL;DR: The use of pre-, pro-, or synbiotics as add-ons in the therapeutic management of psychiatric disorders has been explored as a new way to augment the efficacy of psychotropics and to improve the chances for these patients to reach response or remission as discussed by the authors .
Journal ArticleDOI

Schizophrenia as metabolic disease. What are the causes?

TL;DR: Schizophrenia (SZ) is a devastating neurodevelopmental disease with an accelerated ageing feature as mentioned in this paper , and the criteria of metabolic disease firmly fit with those of schizophrenia, which are at the core of complex pathology.
Journal ArticleDOI

Treatment Resistance in Schizophrenia Is Associated with Attention Deficit/Hyperactivity Disorder and Gut Microbiota: A Genetic Correlation and Mendelian Randomization Study

TL;DR: In this paper , the authors explored the genetic associations between common immune diseases, metabolic diseases, psychiatric disorders, and gut microbiota and found that genus Barnesiella was associated with TRS.
References
More filters
Journal ArticleDOI

A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

TL;DR: In light of the potential for second-generation antipsychotic medications to further adversely influence mortality rates in the decades to come, optimizing the general health of people with schizophrenia warrants urgent attention.
Journal ArticleDOI

Role of the normal gut microbiota

TL;DR: The normal gut microbiota imparts specific function in host nutrient metabolism, xenobiotic and drug metabolism, maintenance of structural integrity of the gut mucosal barrier, immunomodulation, and protection against pathogens.
Journal ArticleDOI

Estimating the true global burden of mental illness.

TL;DR: It is argued that the global burden of mental illness is underestimated and the reasons for under-estimation are examined to identify five main causes: overlap between psychiatric and neurological disorders; the grouping of suicide and self-harm as a separate category; conflation of all chronic pain syndromes with musculoskeletal disorders; exclusion of personality disorders from disease burden calculations; and inadequate consideration of the contribution of severe mental illness to mortality from associated causes.
Journal ArticleDOI

The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice

TL;DR: It is found that unmedicated and medicated patients with SCZ had a decreased microbiome α-diversity index and marked disturbances of gut microbial composition versus healthy controls (HCs), and the SCZ microbiome itself can alter neurochemistry and neurologic function in ways that may be relevant to SCZ pathology.
Journal ArticleDOI

Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis.

TL;DR: Findings show that glucose homeostasis is altered from illness onset in schizophrenia, indicating that patients are at increased risk of diabetes as a result.